NCT03153982View on ClinicalTrials.gov

Ruxolitinib in Operable Head and Neck Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

October 18, 2023

Study Completion Date

October 18, 2023

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Ruxolitinib

Given orally

Trial Locations (2)

85724

University of Arizona Cancer Center, Tucson

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT03153982 - Ruxolitinib in Operable Head and Neck Cancer | Biotech Hunter | Biotech Hunter